Rose Ventures

Xeno Biosciences Inc. is a biotechnology company based in Somerville, Massachusetts, focused on developing innovative treatments for obesity and related metabolic diseases. Founded in 2015, the company is pioneering a novel class of therapeutics designed to mimic the effects of gastric bypass surgery. Its lead product, XEN-101, is an oral formulation that delivers molecular oxygen to the lower gut, facilitating a shift in the gut microbiome toward a state associated with weight loss, similar to the outcomes of Roux-en-Y Gastric Bypass surgery. Through this approach, Xeno Biosciences aims to address significant unmet needs in the management of metabolic disorders.

Invenra Inc. is a biopharmaceutical company specializing in the discovery of biologics, particularly antibodies and their derivatives. Founded in 2011 and located in Madison, Wisconsin, Invenra utilizes a proprietary technology that integrates cell-free expression of full-length antibodies with extreme miniaturization. This innovative approach allows for the screening of a vast number of full-length antibodies in phenotypic assays, facilitating the identification of next-generation biologics. The company boasts a strong scientific foundation and a team of experts with extensive knowledge in genomics, biochemistry, and bioengineering, blending advanced basic research with practical commercial applications.

Producer of skincare products intended to reduce wrinkles and fine lines around the eyes. The company's products use laser technology to treat skin aging and reduce fine lines and wrinkles, enabling users to renew their skin without causing pain or redness while being at home.

Cellular Dynamics International Inc., (CDI) is a developer and manufacturer of fully functioning cells in industrial quantities to precise specifications. CDI's proprietary products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell Products). CDI's products provide standardized, easy-to-use, cost-effective access to the human cell, the smallest fully functioning operating unit of human biology. Customers use our products, among other purposes, for drug discovery and screening, to test the safety and efficacy of their small molecule and biological drug candidates, for stem cell banking, and in the research and development of cellular therapeutics.

Invenra Inc. is a biopharmaceutical company specializing in the discovery of biologics, particularly antibodies and their derivatives. Founded in 2011 and located in Madison, Wisconsin, Invenra utilizes a proprietary technology that integrates cell-free expression of full-length antibodies with extreme miniaturization. This innovative approach allows for the screening of a vast number of full-length antibodies in phenotypic assays, facilitating the identification of next-generation biologics. The company boasts a strong scientific foundation and a team of experts with extensive knowledge in genomics, biochemistry, and bioengineering, blending advanced basic research with practical commercial applications.